Clinical Trials
Enrolling Trials
61-70 of 126
CIRB, Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Lawler, Benjamin E
Central Nervous System
Adult
testing
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
CIRB-A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Abdelhadi, Kareem H
Breast
Adult
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB-A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Tanawattanacharoen, Patcharin
Breast
Adult
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB, Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE)
Tanimu, Sabo B
Cancer Prevention
Adult
FORTE is a colorectal cancer prevention study looking to determine how often participants who have had 1-2 small benign polyps removed during colonoscopy from their colon otherwise known as adenomatous polyps or adenomas should have repeat surveillance colonoscopies. The primary goal of FORTE is to compare the colorectal cancer rates between the two study groups (repeat colonoscopy at 5 and 10 years versus repeat colonoscopy at 10 years) to see if the rates are equivalent. If they are equivalent, then people in the future would likely be recommended to only undergo a 10-year exam and the 5-year exam may not be necessary. Participants will be asked to donate blood and stool samples and will be followed annually.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB; A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Lehman, Elmer G
Gynecologic
Adult
To compare the non inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB-Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
Lauer, Laura M
Breast
Adult
This Phase III trial will examine the efficacy of computerized cognitive training (Brain HQ) compared to the attention control on perceived cognitive impairment post intervention as measured by the FACT-Cog PCI scale.
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB-Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
Husak, Michael
Gastro-Intestinal (GI)
Adult
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Neillsville
216 Sunset Place
Neillsville, Wisconsin 54456
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB, Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy
Fagbemi, Seth O
Genitourinary
Adult
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
DTL - CIRB, Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Yeboah, Isaac
Genitourinary
Adult
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Abiraterone acetate may help fight prostate cancer by lowering the amount of testosterone made by the body. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding abiraterone acetate and apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB - Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Onitilo, Adedayo A
Genitourinary
Adult
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476